

**Title:** Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors

**Authors:** Dr. Colby S. Shemesh\*, Prof. Yongsheng Wang\*, Dr. Andrew An, Ms Hao Ding, Dr. Phyllis Chan, Ms Qi Liu, Dr. Yih-Wen Chen, Dr. Benjamin Wu, Dr. Qiong Wu, Prof. Xian Wang

\*Co-first authors

**Corresponding author:** Colby S. Shemesh, Clinical Pharmacology, Genentech Inc., South San Francisco, CA, USA. E-mail: shemesh.colby@gene.com.

**Journal:** Cancer Chemotherapy and Pharmacology

**Online resource 4** Summary of common ( $\geq 10\%$ ) adverse events by preferred term, safety population from the YP42514 study

| MedDRA preferred term                                           | Tiragolumab plus atezolizumab,<br>N = 20, (%) |
|-----------------------------------------------------------------|-----------------------------------------------|
| <b>Total number of patients with at least one adverse event</b> | 20 (100)                                      |
| Total number of events                                          | 226                                           |
| Aspartate aminotransferase increased                            | 8 (40.0)                                      |
| Rash                                                            | 8 (40.0)                                      |
| Lymphocyte count decreased                                      | 7 (35.0)                                      |
| Pruritus                                                        | 7 (35.0)                                      |
| Alanine aminotransferase increased                              | 6 (30.0)                                      |
| Anemia                                                          | 5 (25.0)                                      |
| Gamma-glutamyl transferase increased                            | 5 (25.0)                                      |
| Hypertriglyceridemia                                            | 5 (25.0)                                      |
| Hypokalemia                                                     | 5 (25.0)                                      |
| Blood alkaline phosphatase increased                            | 4 (20.0)                                      |
| Cough                                                           | 4 (20.0)                                      |
| Hypercholesterolemia                                            | 4 (20.0)                                      |
| Platelet count decreased                                        | 4 (20.0)                                      |
| Proteinuria                                                     | 4 (20.0)                                      |
| Alpha hydroxybutyrate dehydrogenase increased                   | 3 (15.0)                                      |
| Bilirubin conjugated increased                                  | 3 (15.0)                                      |
| Blood bilirubin increased                                       | 3 (15.0)                                      |
| Blood creatine phosphokinase increased                          | 3 (15.0)                                      |
| Blood fibrinogen increased                                      | 3 (15.0)                                      |
| Hyperglycemia                                                   | 3 (15.0)                                      |
| Hyperuricemia                                                   | 3 (15.0)                                      |
| Hypocalcemia                                                    | 3 (15.0)                                      |
| White blood cell count decreased                                | 3 (15.0)                                      |
| Arthropathy                                                     | 2 (10.0)                                      |
| Back pain                                                       | 2 (10.0)                                      |
| Blood ketone body increased                                     | 2 (10.0)                                      |
| Blood lactate dehydrogenase increased                           | 2 (10.0)                                      |
| Chest discomfort                                                | 2 (10.0)                                      |
| Decreased appetite                                              | 2 (10.0)                                      |
| Fatigue                                                         | 2 (10.0)                                      |
| Fibrin D dimer increased                                        | 2 (10.0)                                      |
| Hemoptysis                                                      | 2 (10.0)                                      |
| Hypoalbuminemia                                                 | 2 (10.0)                                      |
| Neutrophil count decreased                                      | 2 (10.0)                                      |
| Pleural effusion                                                | 2 (10.0)                                      |
| Pyrexia                                                         | 2 (10.0)                                      |
| Sinus tachycardia                                               | 2 (10.0)                                      |
| Skin lesion                                                     | 2 (10.0)                                      |
| Vertigo                                                         | 2 (10.0)                                      |
| Weight decreased                                                | 2 (10.0)                                      |

MedDRA, Medical Dictionary for Regulatory Activities.